What is the clinical effectiveness and cost-effectiveness of nebulised saline in patients with chronic obstructive pulmonary disease? (MucAct COPD Trial) We want to study whether breathing in salty water through a nebuliser can help patients with Chronic Obstructive Pulmonary Disease (COPD) cough up phlegm, make them feel better and cut down the number of chest infections. We also would like to know whether this is better than taking tablets (carbocisteine), also thought to help patients clear phlegm from the airways. Chief Investigator: Professor Adam Hill Image Number and location of participating sites (by region/ country): 20 UK SitesEudraCT number: 2020-001949-39ISRCTN number: ISRCTN10249134Funder: National Institute for Health Research Health Technology Assessment Programme (NIHR HTA) Start and End dateOf grant award: 01 June 2020 - 30 June 2025Of recruitment: October 2021 - 01 December 2023 Current Status: Closed to recruitmentTrial Website: NoEmail: MucActCOPD@ed.ac.uk UK GDPR Privacy Statement: As part of Patient Information Sheet Sponsor: ACCORD (https://www.accord.ed.ac.uk/)Chief Investigator: Professor Adam HillAddress: 102 West Port, Edinburgh, EH3 9DNEmail: adam.hill@nhs.scot Trial Manager: Emma Ward Email: MucActCOPD@ed.ac.uk Research Nurse: Sam Donaldson Email: sam.donaldson1@nhs.net and Andrea Clarke Email: andrea.clarke8@nhs.net ECTU involvement: Trial management / Statistics / Health Economics / Data base This article was published on 2024-09-24